ADIPOQ and obesity due to melanocortin 4 receptor deficiency: The current state of knowledge indicates that adiponectins also have antitumor properties in obesity-associated cancers, such as breast, endometrial cancer, by inhibiting the ERK1/2-MAPK pathway [99].